Search clinical trials for: BIBF Paclitaxel

Total 4225 results

Boehringer Ingelheim

Completed

Tolerability of BIBR 953 ZW IV and Bioavailability of BIBR 1048 Tablet and Solution in Healthy Males

Healthy
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics of BIRB 796 BS Tablets Administered to Healthy Human Subjects

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW in Healthy Subjects

Healthy
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific
Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW After Oral Administration of BIBR 1048 MS in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 963 ZW After 50 mg of BIBR 1048 MS With and Without of Pantoprazole in Healthy Subjects

Healthy
Columbia University
Boehringer Ingelheim

Withdrawn

Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment

Esophageal Cancer | Gastrooesophageal Cancer | HER-2 Positive Gastric Cancer
RTI Surgical

Completed

Comparison of nanOss Cervical IBF System to C-Plus PEEK IBF Device With Autograft

Intervertebral Disc Degeneration

Belgium
Boehringer Ingelheim

Completed

Study to Determine Tolerability After Intravenous Administration of BIBN 4096 BS in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Study to Determine Tolerability of Single Increasing Dose of BIBN 4096 BS in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics After Administration of Increasing Dose of BIBN 4096 BS in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Tolerability and Pharmacokinetics/-Dynamics of Single Rising Doses BIBT 986 BS in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BIBW 2948 BS in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Increasing Repeated Doses of BIIF 1149 BS in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetics/Bioavailability of BIBF 1120 Administered to Healthy Male Volunteers

Healthy
JI-YOUN HAN
National Cancer Center, Korea

Completed

BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer

Small Cell Lung Cancer | Small Cell Lung Cancer Recurrent

Korea, Republic of
Boehringer Ingelheim

Completed

A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120

Neoplasms

France, Germany
Boehringer Ingelheim

Completed

A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours

Tumors
Boehringer Ingelheim

Completed

To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours

Malignant Solid Tumour

Germany
Boehringer Ingelheim

Completed

Pharmacokinetics of BIBB 515 BS and Effect of Food After Oral Administration in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics of BIBR 1048 MS Capsule in Healthy Male Subjects of Japanese and Caucasian Origin

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetics of BIBR 277 in Hypertensive Patients

Hypertension
Boehringer Ingelheim

Completed

Effect of BIBT 986 Followed by BIBT 986 Given as IV Infusion on Tissue Factor Triggered Coagulation in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics of Single Rising Doses Oral BIRB 796 BS in Healthy Human Subjects

Healthy
Boehringer Ingelheim

Completed

Single Rising Dose Tolerability Study of BIBN 4096 BS in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Inhalative Administration of BIBN 4096 BS in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)

Pulmonary Fibrosis

Spain, Belgium, Canada, Germany, China, United Kingdom, Australia, Ireland, Italy, Mexico, Netherlands, Portugal, Argentina, France, Russian Federation, Greece, Czechia, Brazil, Bulgaria, Chile, Hungary
Boehringer Ingelheim

Completed

Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients

Pulmonary Fibrosis

United States, Australia, Belgium, China, Czech Republic, France, Germany, India, Ireland, Israel, Italy, Japan, United Kingdom
Boehringer Ingelheim

Completed

An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma
Boehringer Ingelheim

Completed

Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors

Neoplasms

Italy
Boehringer Ingelheim

Completed

An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours

Tumors
National University Hospital, Singapore

Completed

Intragastric Balloon for Treatment of Non Alcoholic Steatohepatitis (NASH)

Non Alcoholic Steatohepatitis

Singapore
Prof. Dr. Wolfgang Wick

Terminated

NOA-12: BIBF1120 and R-RT in Glioblastoma

Glioblastoma Multiforme

Germany
Boehringer Ingelheim

Completed

BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma

Glioma

United States, Canada
Boehringer Ingelheim

Completed

Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 1464 (Tablet) in Hyperlipemic Healthy Male Subjects

Healthy
Patrick Y. Wen, MD
Massachusetts General Hospital; Boehringer Ingelheim; The Cleveland Clinic; Wake... and other collaborators

Completed

BIBF 1120 for Recurrent High-Grade Gliomas

Glioblastoma | Gliosarcoma | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma

United States
Boehringer Ingelheim

Completed

Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer

Prostatic Neoplasms
Chr Hansen

Completed

Efficacy of a Probiotic Strain on Level of Markers of Inflammation in an Elderly Population

Inflammation

Ireland
Boehringer Ingelheim

Completed

Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy

Breast Neoplasms

United States, United Kingdom
Washington University School of Medicine
National Comprehensive Cancer Network

Active, not recruiting

Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung | Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer

United States
AA Secord
Boehringer Ingelheim

Completed

BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
Boehringer Ingelheim

Completed

Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Austria, France, Germany, Hungary, Netherlands, Poland, Romania, United Kingdom
Boehringer Ingelheim

Completed

Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II

Pulmonary Fibrosis

United States, Canada, Chile, China, Finland, France, Germany, Greece, India, Japan, Korea, Republic of, Mexico, Netherlands, Portugal, Russian Federation, Spain, Turkey
Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of [14C]-BIBF 1120 in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.

Carcinoma, Non-Small-Cell Lung

Italy, Netherlands, Spain, United Kingdom
Boehringer Ingelheim

Completed

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States, Spain, Korea, Republic of, Belgium, Australia, United Kingdom, Canada, China, Germany, Japan, Turkey, France, Ireland, Italy, Israel, Netherlands, Portugal, Greece, India, Czechia, Chile, Finland, Mexico, Russian Federation
Boehringer Ingelheim

Completed

A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients

Carcinoma, Hepatocellular

Korea, Republic of, Taiwan
RTI Surgical

Completed

Evaluation of the Fortilink IBF System With TETRAfuse Technology (ENTRUST)

Cervical and Lumbar Fusion

United States
Temple University
Boehringer Ingelheim

Terminated

Continuation of Nintedanib After Single Lung Transplantation in IPF Subjects

Idiopathic Pulmonary Fibrosis | Lung Transplant; Complications

United States
Xtant Medical

Completed

Clinical Evaluation of Fortilink® TETRAfuse® Interbody Fusion Device in Subjects With Degenerative Disc Disease (FORTE)

Degenerative Disc Disease

United States

3

Subscribe